Swedish Orphan Biovitrum (SOBI.ST) breakout from consolidation

34 0
Sanofi's bid yesterday for SOBI's partner Bioverativ at a 60%+ premium is highly supportive for SOBI's valuation. Strong future in haemophilia products Eloctate and Alprolix. As the European territory (SOBI territory) launches were two years later than the US, SOBI's sales are at an earlier stage, and there is strong growth potential as the products move closer to market share achieved in the US. Bioverativ was acquired at 26x 2018 EPS and SOBI currently trades at 15x 2018 EPS . Leading analysts expect SOBI to earn SEK 8,69 per share in 2018 and SEK 11,40 per share in 2019. Thus, we are currently at 12x 2019 EPS for a company that will exceed USD 1 billion in sales this year and grows top line at >20% per annum. A reasonable 12 month target would be industry average 22x 2019 EPS , or SEK 250, roughly double todays share price. The stock has been consolidating for some time, and yesterday broke out on record volume , forming a "cup completion cheat" in Mark Minervini's terms. That is a breakout from a cup and handle formation, where the handle formed in the lower third of the cup.
ZH 繁體中文
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
AR العربية
HE עברית
首頁 股票篩選器 外匯篩選器 加密貨幣篩選器 全球財經日曆 如何運作 圖表功能 網站規則 版主 網站 & 經紀商解決方案 小工具 圖表庫 功能請求 部落格 & 新聞 常見問題 幫助 & 維基 推特
概述 個人資料設定 帳戶和帳單 我的客服工單 聯絡客服 發表的想法 粉絲 正在關注 私人訊息 在線聊天 登出